1. Estimates of SARS-CoV-2 Seroprevalence and Incidence of primary SARS-CoV-2 infections among blood Donors, by COVID-19 vaccination status - United States, April 2021-September 2022;Jones;MMWR Morb. Mortal. Wkly. Rep.,2023
2. SARS-CoV-2 Variants of Concern and Variants under Investigation in England: Technical Briefing vol. 34, https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050236/technical-briefing-34-14-january-2022.pdf (2022).
3. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis;Choi;Nat. Med.,2021
4. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study;Sridhar;Lancet Infect. Dis.,2022
5. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study;de Bruyn;eClinicalMedicine,2023